This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CSPC Pharmaceutical Group Updates Board and Committee Structure

Tipranks - Sat Jun 6, 5:16AM CDT

Claim 55% Off TipRanks

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.

CSPC Pharmaceutical Group has released an updated list of its board of directors and their respective roles, underscoring the company’s governance structure and leadership responsibilities. The board includes a mix of executive and independent non-executive directors, with defined positions such as chairman, vice-chairmen, and chief executive roles to support strategic oversight.

The company also detailed the composition of its key board committees, including audit, nomination, and remuneration, specifying which directors chair or serve as members of each committee. This clarification of committee membership highlights CSPC’s emphasis on transparency, regulatory compliance, and clear accountability in areas such as financial oversight, board appointments, and executive pay, which are important to investors and other stakeholders.

The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing, manufacturing, and marketing a broad range of drug products. The group operates with a structured corporate governance framework overseen by a board comprising executive and independent non-executive directors, reflecting its scale and regulatory obligations in the healthcare sector.

Average Trading Volume: 95,273,554

Technical Sentiment Signal: Hold

Current Market Cap: HK$83.4B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.